The global targeted oncology biologics market is poised for robust expansion, projected to grow from USD 74,751.0 million in 2026 to USD 186,948.7 million by 2036, registering a CAGR of 9.6% over the forecast period, according to Future Market Insights (FMI). This growth is driven by the structural shift in oncology care toward molecularly defined treatment pathways, where therapies...